Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
|Articles|December 21, 2021
Daily Medication Pearl: Vraylar (Cariprazine)
Author(s)Saro Arakelians, PharmD
Vraylar is an atypical antipsychotic indicated for the treatment of adult patients with schizophrenia and for manic, mixed, or depressive episodes for patients with bipolar I disorder.
Advertisement
Medication Pearl of the Day: Vraylar (Cariprazine)
Indication: Vraylar is an atypical antipsychotic indicated for the treatment of schizophrenia in adults, for acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, and for the treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults.
Insight:
- Dosing: Patients can take Vraylar at 1.5 mg to 6 mg daily.
- Dosage forms: Capsules of Vraylar come in dosages of 1.5 mg, 3 mg, 4.5 mg, and 6 mg.
- Adverse events (AEs): Most common AEs include extrapyramidal symptoms and akathisia, extrapyramidal symptoms, akathisia, dyspepsia, vomiting, somnolence, and restlessness.
- Mechanism of action: The efficacy of cariprazine could be mediated through a combination of partial agonist activity at central dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors.
- Manufacturer: Forest Laboratories
Source:
Advertisement
Related to this article
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg per day was linked to more kidney failure and higher all-cause mortality.
A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
Cody Parsons, APh, PharmD, BCCCP, says protected pharmacist access lets patients with heart failure be seen more often than typical clinic visits allow.
The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Understanding Kratom: Pharmacology, Safety, and Regulation
2
How Stanford Pharmacists Help Close Heart Failure Therapy Gaps
3
GLP-1s and Obesity Care: Cardiorenal Outcomes, Prescribing Considerations, and Access Barriers
4
GLP-1 Receptor Agonists and Cancer: Considerations for Specialty Pharmacists
5